Vaccine challenge conjures VaxGen specter

George Miller

Unlike President John F. Kennedy's 1961 mandate to put a man on the moon by the end of that decade, HHS secretary Kathleen Sebelius' mandate for weeks-long vaccine production technology (see related story) is missing the critical deadline component. But you can bet that timelines are already being calculated.

"Viruses are mutating," says Sebelius, in a speech this week. "Terrorists may be planning. The threats we face are always evolving, so our defenses must evolve, too."

Vaccine and manufacturing technologists need to respond to Sebelius, quickly and enthusiastically. Tell her what you need to get the job done, and supply her with the missing deadline.

It's likely that no one in either industry or government wants a repeat of the great vaccine-development debacle of the middle of the last decade. Remember VaxGen, the California biotech flush with Project BioShield funding to supply an anthrax vaccine? The company brought the genetically engineered candidate to the latter stages of development in 2006, when it stalled because of stability issues. VaxGen was unable to meet a contracted milestone date.  The government canceled a 75-million dose order. The company withered and was blown away at the feet of the FDA, which correctly refused to advance a drug that hadn't been proven from a company that appeared unable to finish the job.

The finger-pointing that followed is matched in ugliness only by the amount of taxpayer money wasted. And the incident calls into question two matters, as then reported in the New York Times, that remain today: The ability of small biotechs to deliver on big government contracts, and the ability of the government to manage such projects, given the vagaries of drug development.

So vaccine makers, let's take charge of the process to meet the mandate before someone else does.

George Miller


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.